Structure Therapeutics (NASDAQ:GPCR) Rating Lowered to Strong Sell at Wall Street Zen

Structure Therapeutics (NASDAQ:GPCR) was downgraded by stock analysts at Wall Street Zen from a “sell” rating to a “strong sell” rating in a research note issued on Saturday, Wall Street Zen reports.

GPCR has been the topic of a number of other research reports. Weiss Ratings downgraded Structure Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Friday, September 18th. HC Wainwright reissued a “buy” rating on shares of Structure Therapeutics in a research note on Wednesday, September 9th. Citizens Jmp reissued a “market outperform” rating and set a $110.00 target price on shares of Structure Therapeutics in a research note on Wednesday, September 9th. Canaccord Genuity Group set a $111.00 price objective on Structure Therapeutics in a research note on Friday, August 7th. Finally, Citigroup reiterated a “market outperform” rating on shares of Structure Therapeutics in a report on Friday, August 7th. Two investment analysts have rated the stock with a Strong Buy rating, twelve have assigned a Buy rating, one has given a Hold rating and two have issued a Sell rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $110.91.

Structure Therapeutics Stock Performance

Shares of NASDAQ:GPCR opened at $27.67 on Friday. Structure Therapeutics has a 12-month low of $25.59 and a 12-month high of $94.90. The stock has a market capitalization of $1.93 billion, a price-to-earnings ratio of -27.67 and a beta of -1.30. The stock has a fifty day simple moving average of $44.67 and a two-hundred day simple moving average of $45.71.

Structure Therapeutics (NASDAQ:GPCR) last issued its earnings results on Thursday, August 6th. The company reported ($0.49) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.39) by ($0.10). As a group, equities research analysts predict that Structure Therapeutics will post -1.87 EPS for the current year.

Institutional Trading of Structure Therapeutics

Several institutional investors have recently modified their holdings of the stock. Orbimed Advisors LLC lifted its position in Structure Therapeutics by 27.0% during the first quarter. Orbimed Advisors LLC now owns 1,475,403 shares of the company’s stock worth $71,114,000 after buying an additional 313,600 shares in the last quarter. Squarepoint Ops LLC lifted its holdings in Structure Therapeutics by 454.5% in the second quarter. Squarepoint Ops LLC now owns 125,575 shares of the company’s stock valued at $6,740,000 after acquiring an additional 102,929 shares during the last quarter. Handelsbanken Fonder AB purchased a new position in Structure Therapeutics in the second quarter worth approximately $1,041,000. Wellington Management Group LLP increased its stake in Structure Therapeutics by 1.6% during the second quarter. Wellington Management Group LLP now owns 7,379,433 shares of the company’s stock worth $396,054,000 after acquiring an additional 119,146 shares during the last quarter. Finally, SEB Asset Management AB purchased a new stake in Structure Therapeutics in the first quarter valued at $11,811,000. Institutional investors and hedge funds own 91.78% of the company’s stock.

About Structure Therapeutics

Structure Therapeutics Inc is a clinical-stage biopharmaceutical company developing oral small-molecule medicines for chronic metabolic and cardiopulmonary diseases. The company uses structure-based drug discovery and related technologies to identify therapies intended to address conditions with significant unmet medical needs.

Its lead product candidate is GSBR-1290, an investigational oral small-molecule agonist of the glucagon-like peptide-1 (GLP-1) receptor being developed for obesity and type 2 diabetes.